PharmaLundensis Balance Sheet Health
Financial Health criteria checks 1/6
PharmaLundensis has a total shareholder equity of SEK3.2M and total debt of SEK5.2M, which brings its debt-to-equity ratio to 163.1%. Its total assets and total liabilities are SEK11.0M and SEK7.8M respectively.
Key information
163.1%
Debt to equity ratio
SEK 5.15m
Debt
| Interest coverage ratio | n/a |
| Cash | SEK 2.50m |
| Equity | SEK 3.16m |
| Total liabilities | SEK 7.80m |
| Total assets | SEK 10.96m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: PHAL's short term assets (SEK2.8M) exceed its short term liabilities (SEK2.7M).
Long Term Liabilities: PHAL's short term assets (SEK2.8M) do not cover its long term liabilities (SEK5.2M).
Debt to Equity History and Analysis
Debt Level: PHAL's net debt to equity ratio (84%) is considered high.
Reducing Debt: PHAL's debt to equity ratio has increased from 0% to 163.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PHAL has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if PHAL has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.